ANTIDIABETIC DRUG APPROVED TO REDUCE RISK OF KIDNEY DISEASE

被引：0
|
作者：
Aschenbrenner, Diane S. [1 ,2 ]
机构：
[1] Notre Dame Maryland Univ, Baltimore, MD 21210 USA
[2] Johns Hopkins Univ, Sch Nursing, Baltimore, MD 21218 USA
来源：
AMERICAN JOURNAL OF NURSING | 2021年 / 121卷 / 09期
关键词：
D O I：
暂无
中图分类号：
R47 [护理学];
学科分类号：
1011 ;
摘要：
引用
收藏
页码：25 / 25
页数：1
相关论文
共 50 条
  • [21] A New, Intriguing Hypothesis: Does Bivalirudin Reduce the Risk of Acute Kidney Disease?
    Cortese, Bernardo
    Sciahbasi, Alessandro
    Rigattieri, Stefano
    Ricci, Roberto
    AMERICAN JOURNAL OF CARDIOLOGY, 2015, 115 (04): : 555 - 556
  • [22] Fruit for thought: lifestyle interventions to reduce the risk of future chronic kidney disease
    Lees, Jennifer S.
    Mark, Patrick B.
    NEPHROLOGY DIALYSIS TRANSPLANTATION, 2021, 36 (06) : 963 - 965
  • [23] Antidiabetic herbal drugs officially approved in China
    Jia, W
    Gao, WY
    Tang, L
    PHYTOTHERAPY RESEARCH, 2003, 17 (10) : 1127 - 1134
  • [24] FDA APPROVED DRUG LIBRARY SCREENING TO IDENTIFY COMPOUNDS THAT REDUCE HBS ANTIGEN
    Shimoda, Akiyoshi
    Hikita, Hayato
    Murai, Kazuhiro
    Kuriki, Shinji
    Sometani, Emi
    Sung, Jihyun
    Fukuoka, Makoto
    Shigeno, Satoshi
    Nishio, Akira
    Kodama, Takahiro
    Tatsumi, Tomohide
    Suemizu, Hiroshi
    Takehara, Tetsuo
    HEPATOLOGY, 2023, 78 : S521 - S521
  • [25] 'Approved for use in uveitis': drug approval for an orphan disease
    Metzinger, Jamie Lynne
    Foster, C. Stephen
    EXPERT OPINION ON ORPHAN DRUGS, 2015, 3 (07): : 799 - 807
  • [26] FDA APPROVED DRUG LIBRARY SCREENING TO IDENTIFY COMPOUNDS THAT REDUCE HBS ANTIGEN
    Shimoda, Akiyoshi
    Hikita, Hayato
    Murai, Kazuhiro
    Miyake, Takayuki
    Kuriki, Shinji
    Sometani, Emi
    Sung, Jihyun
    Shigeno, Satoshi
    Shirai, Kumiko
    Tahata, Yuki
    Saito, Yoshinobu
    Kodama, Takahiro
    Tatsumi, Tomohide
    Suemizu, Hiroshi
    Takehara, Tetsuo
    HEPATOLOGY, 2024, 80 : S211 - S212
  • [27] Investigation of imatinib and other approved drugs as starting points for antidiabetic drug discovery with FXR modulating activity
    Steri, Ramona
    Achenbach, Janosch
    Steinhilber, Dieter
    Schubert-Zsilavecz, Manfred
    Proschak, Ewgenij
    BIOCHEMICAL PHARMACOLOGY, 2012, 83 (12) : 1674 - 1681
  • [28] Trends in Antidiabetic Drug Discovery: FDA Approved Drugs, New Drugs in Clinical Trials and Global Sales
    Dahlen, Amelia D.
    Dashi, Giovanna
    Maslov, Ivan
    Attwood, Misty M.
    Jonsson, Joergen
    Trukhan, Vladimir
    Schioth, Helgi B.
    FRONTIERS IN PHARMACOLOGY, 2022, 12
  • [29] Assessing adverse drug reaction reports for antidiabetic medications approved by the food and drug administration between 2012 and 2017: a pharmacovigilance study
    Stottlemyer, Britney A.
    McDermott, Michael C.
    Minogue, Mackenzie R.
    Gray, Matthew P.
    Boyce, Richard D.
    Kane-Gill, Sandra L.
    THERAPEUTIC ADVANCES IN DRUG SAFETY, 2023, 14
  • [30] Impact of Oral Antidiabetic Drugs on Development of Chronic Kidney Disease
    Masica, Andrew
    Daoud, Yahya
    West, Suzanne
    PHARMACOEPIDEMIOLOGY AND DRUG SAFETY, 2011, 20 : S327 - S327
12345